The Association between CDKAL1 Gene rs10946398 Polymorphism and Post-Transplant Diabetes in Kidney Allograft

Violetta Dziedziejko1, Krzysztof Safranow1, Mirosława Kijko-Nowak2

  • 1Department of Biochemistry and Medical Chemistry, Pomeranian Medical University, 70-204 Szczecin, Poland.

Genes
|August 26, 2023
PubMed

Insights

The CDKAL1 rs10946398 CC genotype is linked to a higher risk of developing post-transplant diabetes mellitus (PTDM) in kidney transplant patients treated with tacrolimus. Advanced age also emerged as a significant risk factor for PTDM.

Area of Science:

  • Nephrology
  • Genetics
  • Endocrinology

Background:

  • Post-transplant diabetes mellitus (PTDM) is a frequent complication following kidney transplantation, associated with increased morbidity and graft dysfunction.
  • Identifying genetic factors influencing carbohydrate metabolism may help predict PTDM risk.

Purpose of the Study:

  • To investigate the association between specific gene polymorphisms (CDKAL1 rs10946398, GCK rs1799884, GCKR rs780094, DGKB/TMEM195 rs2191349) and the development of PTDM in kidney transplant recipients.

Main Methods:

  • A cohort of 201 Caucasian kidney transplant patients treated with tacrolimus was analyzed.
  • Genotyping for selected polymorphisms was performed, and associations with PTDM development were assessed using statistical analyses, including logistic regression.

Main Results:

  • A significant association was found between the CDKAL1 rs10946398 polymorphism and PTDM. Patients with the CC genotype had a 2.60-fold higher risk of developing PTDM compared to those with AC/AA genotypes (OR: 2.60, 95% CI: 1.02-6.61, p=0.040).
  • Multivariate analysis identified advanced age and the CDKAL1 rs10946398 CC genotype as independent risk factors for PTDM at one year post-transplantation.
  • No significant associations were observed for GCK rs1799884, GCKR rs780094, or DGKB/TMEM195 rs2191349 polymorphisms with PTDM development.

Conclusions:

  • The CDKAL1 rs10946398 CC genotype is a potential genetic marker associated with an increased risk of PTDM in kidney transplant recipients on tacrolimus therapy.
  • These findings may contribute to personalized risk assessment and management strategies for PTDM in kidney transplant patients.